Pub Date : 2020-03-06DOI: 10.19080/ctoij.2020.16.555940
Qurat-ul-ain, S. Hussain, M. I. Coudhary, K. Khan
A library of substituted pyrimidines was synthesized and evaluated for free radical scavenging, and in vitro cytotoxic activity in 3T3 cells. All compounds showed good free radical scavenging activity with IC50 values in the range of 42.9 + 0.31 to 438.3 3.3 {mu}M as compared to the standard butylated hydroxytoluene having IC50 value of 128.83 2. 1 {mu}M. The structure activity-relationship was also established. Selected analogues 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 15, 19, 20, 21, 24, 25, 26 and 28 were tested for cytotoxicity in mouse fibroblast 3T3 cell line using MTT assay, and most of the analogues showed cytotoxicity. This study has identified a number of cytotoxic novel substituted pyrimidines having free radical scavenging activities that can be used as inhibitory compounds for those cancer cells whose growth is mediated by reactive oxygen species.
{"title":"Free Radical Scavenging and Cytotoxic Activities of Substituted Pyrimidines","authors":"Qurat-ul-ain, S. Hussain, M. I. Coudhary, K. Khan","doi":"10.19080/ctoij.2020.16.555940","DOIUrl":"https://doi.org/10.19080/ctoij.2020.16.555940","url":null,"abstract":"A library of substituted pyrimidines was synthesized and evaluated for free radical scavenging, and in vitro cytotoxic activity in 3T3 cells. All compounds showed good free radical scavenging activity with IC50 values in the range of 42.9 + 0.31 to 438.3 3.3 {mu}M as compared to the standard butylated hydroxytoluene having IC50 value of 128.83 2. 1 {mu}M. The structure activity-relationship was also established. Selected analogues 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 15, 19, 20, 21, 24, 25, 26 and 28 were tested for cytotoxicity in mouse fibroblast 3T3 cell line using MTT assay, and most of the analogues showed cytotoxicity. This study has identified a number of cytotoxic novel substituted pyrimidines having free radical scavenging activities that can be used as inhibitory compounds for those cancer cells whose growth is mediated by reactive oxygen species.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88517669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-06DOI: 10.19080/CTOIJ.2020.15.555925
R. Tellez
In general, Glioblastomas multiforme frequently occurs in supratentorial region but in less than 4% occur in the posterior fossa predominantly in the cerebellum, and spinal cords tumors represents 6% to 8% of all central nervous system tumors and spinal cord glioblastomas occur only in 1.5% of all spinal cords tumors. We presents two cases a male whit posterior fossa glioblastoma and a girl with spinal cord glioblastoma in both cases, MRI is the study of choice with high sensitivity and specificity for diagnosis, after that they underwent biopsy and the results of pathology described GBM in both cases. The treatment of election is radiotherapy plus chemotherapy and surge if is possible, the prognosis is poor even with treatment, thats is why we need to identify new therapeutic strategies; We currently believe
{"title":"Unusual presentations of Glioblastoma Posterior Fossa and spinal cord: Cases Presentations and Review of Literature","authors":"R. Tellez","doi":"10.19080/CTOIJ.2020.15.555925","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555925","url":null,"abstract":"In general, Glioblastomas multiforme frequently occurs in supratentorial region but in less than 4% occur in the posterior fossa predominantly in the cerebellum, and spinal cords tumors represents 6% to 8% of all central nervous system tumors and spinal cord glioblastomas occur only in 1.5% of all spinal cords tumors. We presents two cases a male whit posterior fossa glioblastoma and a girl with spinal cord glioblastoma in both cases, MRI is the study of choice with high sensitivity and specificity for diagnosis, after that they underwent biopsy and the results of pathology described GBM in both cases. The treatment of election is radiotherapy plus chemotherapy and surge if is possible, the prognosis is poor even with treatment, thats is why we need to identify new therapeutic strategies; We currently believe","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89558706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-20DOI: 10.19080/CTOIJ.2020.15.555922
A. Strombom
Treatment of early stage prostate cancer (with a Gleason score less than seven) with a plant-based diet has been studied, and efficacy noted even after 5 years [1]. However, this is a case of a patient with Stage 3 prostate cancer, who chose to follow a plantbased diet after his diagnosis, and is still alive today, 32 years later, despite being given only a 10% chance of 3 year survival. While this case is anecdotal, and a plant-based diet was combined with standard treatment, it joins a growing body of evidence that prostate cancer is responsive to treatment with a plant-based diet. The patient’s longevity may also partially be the result of a plant-based diet preventing and treating common comorbidities such coronary artery disease [2], Type 2 diabetes [3], and renal failure [4].
{"title":"Stage 3 Prostate Cancer Treated with a Plant-Based Diet – A Case Report","authors":"A. Strombom","doi":"10.19080/CTOIJ.2020.15.555922","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555922","url":null,"abstract":"Treatment of early stage prostate cancer (with a Gleason score less than seven) with a plant-based diet has been studied, and efficacy noted even after 5 years [1]. However, this is a case of a patient with Stage 3 prostate cancer, who chose to follow a plantbased diet after his diagnosis, and is still alive today, 32 years later, despite being given only a 10% chance of 3 year survival. While this case is anecdotal, and a plant-based diet was combined with standard treatment, it joins a growing body of evidence that prostate cancer is responsive to treatment with a plant-based diet. The patient’s longevity may also partially be the result of a plant-based diet preventing and treating common comorbidities such coronary artery disease [2], Type 2 diabetes [3], and renal failure [4].","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74875185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-18DOI: 10.19080/CTOIJ.2020.15.555920
C. S. Kunak
Mostly observed in men, lung carcinoma, mostly observed in men, is one of the most frequent cancer types in Turkey and in the world. About two thirds of the lung carcinoma patients have inoperable lesions. 113 primary lung cancer patients who were receiving platinum based treatment at Chest Diseases and Chest Surgery Center of Ankara Atatürk Hospital were enrolled for the study. It was identified that 49 (43%) patients had GSTM1 gene deletion out of a group of 113. It was identified that 42 (%), 34 (39%) and 10 (12%) patients had 105 (wild type) genotype, İ le 105 /Val 105 (heterozygote) genotype and Val 105 /Val 105 (homozygote mutant) genotype, respectively out of a group of 113. GSTP1 is the most strongly expressed isoenzyme in the human lung. In this study, the responses to cisplatine based chemotherapy of homozygous and heterozygous patients with GSTP1 exon5 variant allele were observed to be similar to the responses of the patients carrying wild type genotype. it is displayed that wild type genes have positive effect on the response to treatment. This result yields that it is important to evaluate the effect of combination of GST genotype, alcohol ingestion amount, smoking frequency on the response to treatment
肺癌主要在男性中观察到，是土耳其和世界上最常见的癌症类型之一。大约三分之二的肺癌患者有不能手术的病变。研究纳入了113名在安卡拉atatrk医院胸部疾病和胸部外科中心接受铂基治疗的原发性肺癌患者。结果发现，113例患者中有49例(43%)存在GSTM1基因缺失。113例患者中，105(野生型)、İ le 105 /Val 105(杂合子)和Val 105 /Val 105(纯合子突变)基因型分别为42例(%)、34例(39%)和10例(12%)。GSTP1是人肺中表达最强烈的同工酶。在本研究中，观察到GSTP1外显子5变异等位基因纯合子和杂合子患者对顺铂化疗的反应与携带野生型基因型患者的反应相似。结果表明，野生型基因对治疗反应有积极作用。结果表明，评价GST基因型、酒精摄入量、吸烟频率对治疗效果的影响具有重要意义
{"title":"Glutathione S-transferase Isoenzymes in Lung Carcinoma Patients receiving Platinum-based Chemotherapy and Effects of Ethyl Alcohol and Smoking on Treatment Response","authors":"C. S. Kunak","doi":"10.19080/CTOIJ.2020.15.555920","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555920","url":null,"abstract":"Mostly observed in men, lung carcinoma, mostly observed in men, is one of the most frequent cancer types in Turkey and in the world. About two thirds of the lung carcinoma patients have inoperable lesions. 113 primary lung cancer patients who were receiving platinum based treatment at Chest Diseases and Chest Surgery Center of Ankara Atatürk Hospital were enrolled for the study. It was identified that 49 (43%) patients had GSTM1 gene deletion out of a group of 113. It was identified that 42 (%), 34 (39%) and 10 (12%) patients had 105 (wild type) genotype, İ le 105 /Val 105 (heterozygote) genotype and Val 105 /Val 105 (homozygote mutant) genotype, respectively out of a group of 113. GSTP1 is the most strongly expressed isoenzyme in the human lung. In this study, the responses to cisplatine based chemotherapy of homozygous and heterozygous patients with GSTP1 exon5 variant allele were observed to be similar to the responses of the patients carrying wild type genotype. it is displayed that wild type genes have positive effect on the response to treatment. This result yields that it is important to evaluate the effect of combination of GST genotype, alcohol ingestion amount, smoking frequency on the response to treatment","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72735034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-18DOI: 10.19080/CTOIJ.2020.15.555921
A. Yousef
Male breast cancer is a rare malignancy accounting for < 1% of all cancers in men and < 1% of all breast cancers. Most of the cases are advanced stage ductal invasive carcinomas and express hormone receptors in the great majority and are less likely to over-express HER2-neu. Treatment includes locoregional methods such as surgery and radiotherapy, and systemic treatment mainly with hormonal therapy and, to a lesser extent, trastuzumab and chemotherapy as second lines. Nonetheless, the optimal treatment for male breast cancer is not known due to lack of prospective randomized trials. In this review systemic therapy for male breast cancer is discussed in the neoadjuvant and adjuvant settings, with insight into the treatment of advanced disease.
{"title":"Systemic Therapy for Male Breast Cancer","authors":"A. Yousef","doi":"10.19080/CTOIJ.2020.15.555921","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555921","url":null,"abstract":"Male breast cancer is a rare malignancy accounting for < 1% of all cancers in men and < 1% of all breast cancers. Most of the cases are advanced stage ductal invasive carcinomas and express hormone receptors in the great majority and are less likely to over-express HER2-neu. Treatment includes locoregional methods such as surgery and radiotherapy, and systemic treatment mainly with hormonal therapy and, to a lesser extent, trastuzumab and chemotherapy as second lines. Nonetheless, the optimal treatment for male breast cancer is not known due to lack of prospective randomized trials. In this review systemic therapy for male breast cancer is discussed in the neoadjuvant and adjuvant settings, with insight into the treatment of advanced disease.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75051509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-31DOI: 10.19080/CTOIJ.2020.15.555917
O. Sager
Objective: Cerebral cavernous malformations (CCMs) are composed of abnormal hyalinized capillary clusters typically surrounded by deposits of hemosiderin. These vascular abnormalities of the brain may be asymptomatic, however, a plethora of symptoms may occur in some of the affected patients including seizures, hemorrhages, and neurological deficits. Stereotactic radiosurgery (SRS) has been utilized as a noninvasive modality of management for selected patients with high risk CCMs located at eloquent brain regions typically not amenable to surgical removal. In this study, we assessed incorporation of multimodality imaging into target volume definition of CCM radiosurgery. Materials and methods: Twenty-three patients treated with SRS for CCM at our institution were included. Target definition with CT only and by incorporation of CT-MR fusion was comparatively evaluated. Results: Twenty-three patients receiving SRS for CCMs at our institution were evaluated for target volume determination using CT-only imaging and CT-MR fusion based imaging. Ground truth target volume defined by treating physicians after comprehensive assessment and consensus was identical to target definition using CT-MR fusion based imaging in the majority of patients. Conclusion: MRI may be utilized for improving the definition of SRS target for CCM management.
{"title":"Target Volume Definition for Stereotactic Radiosurgery (SRS) Of Cerebral Cavernous Malformations (CCMS)","authors":"O. Sager","doi":"10.19080/CTOIJ.2020.15.555917","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555917","url":null,"abstract":"Objective: Cerebral cavernous malformations (CCMs) are composed of abnormal hyalinized capillary clusters typically surrounded by deposits of hemosiderin. These vascular abnormalities of the brain may be asymptomatic, however, a plethora of symptoms may occur in some of the affected patients including seizures, hemorrhages, and neurological deficits. Stereotactic radiosurgery (SRS) has been utilized as a noninvasive modality of management for selected patients with high risk CCMs located at eloquent brain regions typically not amenable to surgical removal. In this study, we assessed incorporation of multimodality imaging into target volume definition of CCM radiosurgery. Materials and methods: Twenty-three patients treated with SRS for CCM at our institution were included. Target definition with CT only and by incorporation of CT-MR fusion was comparatively evaluated. Results: Twenty-three patients receiving SRS for CCMs at our institution were evaluated for target volume determination using CT-only imaging and CT-MR fusion based imaging. Ground truth target volume defined by treating physicians after comprehensive assessment and consensus was identical to target definition using CT-MR fusion based imaging in the majority of patients. Conclusion: MRI may be utilized for improving the definition of SRS target for CCM management.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77131129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-24DOI: 10.19080/CTOIJ.2020.15.555515
Chandana Sanjee
4.7-Abstract Aim: Estimate deficiency in target volume coverage when using conventional X ray-based planning using bony landmarks in carcinoma rectum. Methods and Material: The study consists of 86 biopsy proven patients of carcinoma rectum. The planned area of treatment was demarcated as per 2D bony landmarks in AP and lateral portals were used following which a 3-field plan was created. This plan was projected on a CT scan in which gross tumour volume, clinical target volume and planning target volume were delineated as per RTOG guidelines, thus comparing 2 dimensional vs. 3 dimensional techniques of treatment. Geographic miss of the nodal target when using conventional technique was estimated in comparison to 3D volume planning on the CT scan. Statistical analysis used: Data were statistically described in terms of mean ± standard deviation, median, and range. Comparison between the study plans was done using Chi square test. P < 0.05 was considered statistically significant. All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Results: When the PTV was superimposed on digital reconstructed radiograph (DRR), 32 out of 86 patients had geographical miss at the superior border, hence missing to cover the internal iliac group of lymph nodes when conventional 2-dimensional techniques were used to delineate target volume. When 2D plan coverage was superimposed on 3D volume DRR, volume receiving 95% of dose was 93% in the 2D plan whereas the coverage of V95 was 98 % (p value 0.01) in 3DCRT plan. The geographic miss of nodal target volume was 1.4cm superiorly. When this missed volume was included into the target and planned, PTV coverage was achieved and small bowel dose was within the planned constraint of V40<30%. Conclusion: CT based planning should be encouraged and in radiation departments where 2-dimensional treatment is practiced, a diagnostic CT scan should be recommended, and the radiation portals should be revised as per the findings of the scan.
目的:利用传统的基于X线的直肠癌骨标记规划评估靶体积覆盖的不足。方法和材料:本研究包括86例经活检证实的直肠癌患者。根据AP的2D骨地标划定治疗计划区域，并使用侧门静脉，然后创建3场计划。该计划被投射到CT扫描上，根据RTOG指南划定肿瘤总体积、临床靶体积和计划靶体积，从而比较二维和三维治疗技术。与CT扫描的三维体积规划相比，使用传统技术估计节点目标的地理缺失。采用统计分析:数据以均数±标准差、中位数和极差进行统计描述。研究计划间的比较采用卡方检验。P < 0.05为差异有统计学意义。所有统计计算均使用SPSS (statistical Package for Social Science;SPSS Inc.， Chicago, IL, USA) version 15 for Microsoft Windows。结果:当PTV与数字重建x线片(DRR)叠加时，86例患者中有32例在上边界有地理遗漏，因此在使用常规二维技术划定靶体积时，遗漏了覆盖髂内淋巴结组。当2D计划覆盖率叠加在3D体积DRR上时，2D计划中95%剂量的体积覆盖率为93%，而3DCRT计划中V95覆盖率为98% (p值0.01)。淋巴结靶体积的地理缺失量优势为1.4cm。当这一遗漏量被纳入目标和计划时，PTV覆盖率得以实现，小肠剂量在V40<30%的计划限制范围内。结论:应鼓励基于CT的规划，在实施二维治疗的放射科，应推荐诊断性CT扫描，并根据扫描结果修改放射入口。
{"title":"Is three-Dimensional CT based Conformal Radiotherapy Superior to Two-dimensional X ray-based Radiotherapy for Neoadjuvant Radiotherapy in Locally advanced Carcinoma Rectum?","authors":"Chandana Sanjee","doi":"10.19080/CTOIJ.2020.15.555515","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555515","url":null,"abstract":"4.7-Abstract Aim: Estimate deficiency in target volume coverage when using conventional X ray-based planning using bony landmarks in carcinoma rectum. Methods and Material: The study consists of 86 biopsy proven patients of carcinoma rectum. The planned area of treatment was demarcated as per 2D bony landmarks in AP and lateral portals were used following which a 3-field plan was created. This plan was projected on a CT scan in which gross tumour volume, clinical target volume and planning target volume were delineated as per RTOG guidelines, thus comparing 2 dimensional vs. 3 dimensional techniques of treatment. Geographic miss of the nodal target when using conventional technique was estimated in comparison to 3D volume planning on the CT scan. Statistical analysis used: Data were statistically described in terms of mean ± standard deviation, median, and range. Comparison between the study plans was done using Chi square test. P < 0.05 was considered statistically significant. All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows. Results: When the PTV was superimposed on digital reconstructed radiograph (DRR), 32 out of 86 patients had geographical miss at the superior border, hence missing to cover the internal iliac group of lymph nodes when conventional 2-dimensional techniques were used to delineate target volume. When 2D plan coverage was superimposed on 3D volume DRR, volume receiving 95% of dose was 93% in the 2D plan whereas the coverage of V95 was 98 % (p value 0.01) in 3DCRT plan. The geographic miss of nodal target volume was 1.4cm superiorly. When this missed volume was included into the target and planned, PTV coverage was achieved and small bowel dose was within the planned constraint of V40<30%. Conclusion: CT based planning should be encouraged and in radiation departments where 2-dimensional treatment is practiced, a diagnostic CT scan should be recommended, and the radiation portals should be revised as per the findings of the scan.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74077962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-23DOI: 10.19080/CTOIJ.2020.15.555914
P. K. Shahi
Background: Liver abscesses are uncommon, but they are associated with a hospital mortality rate of 10% in patients without cancer. However, its relevance in cancer patients in terms of survival and length of hospitalization is unknown. Patients and Methods: We conducted an observational study in order to analyze the impact of liver abscesses in hospitalized cancer patients. Eligible patients were adults with a solid tumor, received antineoplastic treatment and were hospitalized in our department with a diagnosis of liver abscesses. Primary end-points of the study were overall survival (OS) and mean hospital stay (MHS). Secondary end-points were the description of risk factors of liver abscesses, isolated microorganisms and the specific treatment. Results: In our study the incidence of liver abscesses in cancer patients was 1.85%. Median age was 64 years, 60% were men, and the vast majority of patients had an advanced bilio-pancreatic tumor (80%). With a median follow-up of 18 months, median OS was 6 months (95% CI: 1-12); and OS probability at 18-month was 27%. MHS was 30.5 days (95% CI: 20.3-40.7). Risk factors for developing liver abscesses were: a) bilio-pancreatic cancers; b) chemotherapy administration; c) severe malnutrition; and d) biliary drainage/prosthesis. Eight patients (53.3%) had bacteremia, and the most common isolated microorganism was E.coli (33.3%). Percutaneous drainage of abscesses was performed in 53.3% of the patients, and all patients were treated with broad-spectrum antibiotics. Conclusion: Although liver abscesses were uncommon, they were associated with a prolonged hospitalization and poor outcome in cancer patients.
{"title":"Poor Outcome and Prolonged Hospital Stay after the Diagnosis of Liver Abscesses in Hospitalized Cancer Patients: A Single Center Experience","authors":"P. K. Shahi","doi":"10.19080/CTOIJ.2020.15.555914","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555914","url":null,"abstract":"Background: Liver abscesses are uncommon, but they are associated with a hospital mortality rate of 10% in patients without cancer. However, its relevance in cancer patients in terms of survival and length of hospitalization is unknown. Patients and Methods: We conducted an observational study in order to analyze the impact of liver abscesses in hospitalized cancer patients. Eligible patients were adults with a solid tumor, received antineoplastic treatment and were hospitalized in our department with a diagnosis of liver abscesses. Primary end-points of the study were overall survival (OS) and mean hospital stay (MHS). Secondary end-points were the description of risk factors of liver abscesses, isolated microorganisms and the specific treatment. Results: In our study the incidence of liver abscesses in cancer patients was 1.85%. Median age was 64 years, 60% were men, and the vast majority of patients had an advanced bilio-pancreatic tumor (80%). With a median follow-up of 18 months, median OS was 6 months (95% CI: 1-12); and OS probability at 18-month was 27%. MHS was 30.5 days (95% CI: 20.3-40.7). Risk factors for developing liver abscesses were: a) bilio-pancreatic cancers; b) chemotherapy administration; c) severe malnutrition; and d) biliary drainage/prosthesis. Eight patients (53.3%) had bacteremia, and the most common isolated microorganism was E.coli (33.3%). Percutaneous drainage of abscesses was performed in 53.3% of the patients, and all patients were treated with broad-spectrum antibiotics. Conclusion: Although liver abscesses were uncommon, they were associated with a prolonged hospitalization and poor outcome in cancer patients.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78775687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-22DOI: 10.19080/CTOIJ.2020.15.555913
N. Hamed
This article tries to answer the following questions i. Is it necessary to incorporate cytogenetic risk categorization in induction decision making?
本文试图回答以下问题1 .是否有必要在诱导决策中纳入细胞遗传学风险分类?
{"title":"Update in treatment of Symptomatic newly Diagnosed Transplant Eligible Multiple Myeloma Patients","authors":"N. Hamed","doi":"10.19080/CTOIJ.2020.15.555913","DOIUrl":"https://doi.org/10.19080/CTOIJ.2020.15.555913","url":null,"abstract":"This article tries to answer the following questions i. Is it necessary to incorporate cytogenetic risk categorization in induction decision making?","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80861041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：